Zydus Cadila has received final approval from the US health regulator to market Zolmitriptan tablets, used to relieve headache, pain, and other migraine symptoms.
According to a BSE filing, the company has got final approval from the US Food and Drug Administration (USFDA) to market the drug in the strengths of 2.5 mg and 5 mg. The drug will be produced at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The Zydus group has more than 203 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it had started filings in 2003-04.
Shares of Cadila Healthcare, the listed entity of the group, were trading 0.34 per cent lower at Rs 370.25 per scrip on the BSE.